苏拉明在肝纤维化大鼠肝星状细胞增殖和凋亡中的作用

doi:10.5246/jcps.2011.04.053

• 研究论文 • 上一篇

苏拉明在肝纤维化大鼠肝星状细胞增殖和凋亡中的作用

陈新, 修贺明, 姜慧卿^*

1. 北京市垂杨柳医院儿科, 北京 100022
2. 河北医科大学第二医院消化科河北省消化病重点实验室河北省消化病研究所, 河北石家庄 050051

收稿日期:2011-03-14 修回日期:2011-05-30 出版日期:2011-07-01 发布日期:2011-07-01
通讯作者: 姜慧卿*

Effects of suramin on proliferation and apoptosis of hepatic stellate cells of hepatic fibrosis rats

Xin Chen, He-Ming Xiu, Hui-Qing Jiang^*

1. Department of Pediatrics, Chuiyangliu Hospital of Beijing, Beijing 100022, China
2. Department of Gastroenterology, The Second Hospital of Hebei Medical University, Hebei Key Laboratory of Gastroenterology, Hebei Institute of Gastroenterology, Shijiazhuang 050051, China

Received:2011-03-14 Revised:2011-05-30 Online:2011-07-01 Published:2011-07-01
Contact: Hui-Qing Jiang*

摘要/Abstract

摘要：

本研究旨在探究苏拉明在肝星状细胞(HSCs)增殖、凋亡中的作用。将HSCs株分别在不同浓度的苏拉明和无苏拉明的培养基中体外培养。应用MTT法检测细胞增殖率; 流式细胞术测定细胞周期和增殖指数; TUNEL法检测细胞凋亡率; 显微镜下观察细胞形态学变化。结果显示苏拉明干预后, 与对照组比较HSCs增殖率均显著减低; 苏拉明(1.4×10^–5mol/L)干预 72小时, HSCs增殖率降低最明显, 且呈时间和剂量依赖性; 苏拉明(1.4×10^–5mol/L)干预24小时, G1期HSCs百分比显著升高, 增殖指数显著降低, 而HSCs凋亡率无显著变化。苏拉明对HSCs形态无显著影响。我们认为在实验剂量范围内, 苏拉明可抑制HSCs增殖, 而对HSCs凋亡无影响。

关键词: 苏拉明, 肝星状细胞, 增殖, 凋亡, 肝纤维化

Abstract:

The aim of the study was to investigate the role of suramin in the proliferation and apoptosis of activated hepatic stellate cells (HSCs). HSCs were cultured in medium with different doses of suramin. The cell proliferation rate was determined using methyl thiazolyl tetrazolium (MTT) assay. Both the cell cycle and proliferation index (PRI) were analyzed using flow cytometry. The apoptotic rate of HSCs was measured using TdT-mediated dUTP nick end labeling (TUNEL) method. The conformation of HSCs was observed using microscopy. The results indicated that the HSCs proliferation rate of suramin treated cells was significantly reduced compared to the control cells. After HSCs were treated with suramin for 72 h, the cell proliferation rate reached the lowest value compared to the control cells. Our results indicated that suramin inhibited the proliferation of HSCs in a time- and dose-dependent manner. After HSCs were treated with suramin for 24 h, the percentage of HSCs in the G1 phase exhibited a significant increase, the PRI showed a remarkable decrease, while the HSCs apoptosis rate did not show any obvious change. In addition, it seemed that suramin failed to affect the conformation of HSCs. Our data suggested that within the dose range used in the present study, suramin inhibited the proliferation of HSCs, but it could not induce HSCs apoptosis.

Key words: Suramin, Hepatic stellate cells, Proliferation, Apoptosis, Hepatic fibrosis

中图分类号:

R575.2

Supporting:

^*Corresponding author. Tel.: 86-311-66002955; E-mail: huiqingjiang@yahoo.com.cn

陈新, 修贺明, 姜慧卿^*. 苏拉明在肝纤维化大鼠肝星状细胞增殖和凋亡中的作用[J]. , DOI: 10.5246/jcps.2011.04.053.

Xin Chen, He-Ming Xiu, Hui-Qing Jiang^*. Effects of suramin on proliferation and apoptosis of hepatic stellate cells of hepatic fibrosis rats[J]. , DOI: 10.5246/jcps.2011.04.053.

参考文献

[1] Wang, J.Y.; Zhang, Q.S.; Guo, J.S.; Hu, M.Y. World J. Gastroenterol. 2001, 7, 115-119.
[2] Svegliati-Baroni, G.; Ridolfi, F.; Di Sario, A.; Saccomanno, S.; Bendia, E.; Benedetti, A. Hepatology. 2001, 33, 1130-1140.
[3] Pinzani, M. Pharmacol. Ther. 1995, 66, 387-412.
[4] Blomhoff, R.; Wake, K. FASEB J. 1991, 5, 271-277.
[5] Friedman, S.L. J. Biol. Chem. 2000, 275, 2247-2250.
[6] Hautekeete, M.L.; Geerts, A. Virchows Arch. 1997, 430, 195-207.
[7] Vasiliou, V.; Lee, J.; Pappa, A.; Petersen, D.R. Biochem. Biophys. Res. Commun. 2000, 273, 546-550.
[8] Kato, R.; Kamiya, S.; Ueki, M.; Yajima, H.; Ishii, T.; Nakamura, H. Exp. Cell Res. 2001, 265, 54-63.
[9] Lang, A.; Schoonhoven, R.; Tuvia, S.; Brenner, D.A.; Rippe, R.A. J. Hepatol. 2000, 33, 49-58.
[10] Liang, Y.; Jansen, M.; Aronow, B.; Geiger, H.; Van Zant, G. Nat. Genet. 2007, 39, 178-188.
[11] Iwamoto, H.; Sakai, H.; Tada, S.; Nakamuta, M.; Nawata, H. J. Lab. Clin. Med. 1999, 134, 83-89.
[12] Kisseleva, T.; Brenner, D.A. J. Gastroenterol. Hepatol. 2006, 3, S84-87.
[13] Fischer, R.; Schmitt, M.; Bode, J.G.; Haussinger, D. Gastroenterology. 2001, 120, 1212-1226.
[14] Issa, R.; Williams, E.; Trim, N.; Kendall, T.; Arthur, M.J.; Reichen, J. Gut. 2001, 48, 548-557.
[15] Zhong, Q.L.; Luo, H.S.; Zhang, J. Chin. J. Gastroenterol. Hepatol. 2009, 18, 907-910.
[16] Dranoff, J.A.; Ogawa, M.; Kruglov, E.A.; Gaca, M.D.; Sevigny, J.; Robson, S.C. Am. J. Physiol. Gastrointest. Liver Physiol. 2004, 287, G417-424.
[17] Kaur, M.; Reed, E.; Sartor, O.; Dahut, W.; Figg, W.D. Invest. New Drugs. 2002, 20, 209-219.
[18] Lossos, I.S.; Izbicki, G.; Or, R.; Goldstein, R.H.; Breuer, R. Life Sci. 2000, 67, 2873-2881.
[19] Zhong, Q.L.; Luo, H.S.; Zhang, J. Chin. J. Gastroenterol. Hepatol. 2009, 18, 907-910.
[20] Greenwel, P.; Schwartz, M.; Rosas, M.; Peyrol, S.; Grimaud, J.A.; Rojkind, M. Lab. Invest. 1991, 65, 644-653.
[21] Engisch, R.; Schurmann, K.; Bienert, H. J. Vasc. Interv. Radiol. 2000, 11, 639-644.
[22] Rieck, P.; Kriegsch, J.; Jaeckel, C. Ophthalmologe. 2004, 101, 73-79.
[23] Eichhorst, S.T.; Krueger, A.; Muerkoster, S.; Fas, S.C.; Golks, A.; Gruetzner, U. Nat. Med. 2004, 10, 602-609.
[24] Bitton, R.J.; Figg, W.D.; Venzon, D.J.; Dalakas, M.C.; Bowden, C.; Headlee, D. J. Clin. Oncol. 1995, 13, 2223-2229.
[25] Coffey, R.J.Jr.; Leof, E.B.; Shipley, G.D.; Moses, H.L. J. Cell Physiol. 1987, 132, 143-148.
[26] Hu, Y.; Zon, Y.; Dietrich, H.; Wick, G.; Xu, Q. Circulation. 1999, 100, 861-868.
[27] Cha, S.H.; Hahn, T.W.; Sekine, T.; Lee, K.H.; Endou, H. Jpn. J. Pharmacol. 2000, 82, 181-187.
[28] Li, C.; Jiang, X.; Yang, L.; Liu, X.; Yue, S.; Li, L. Am. J. Pathol. 2009, 175, 1464-1472.
[29] Li, C.; Kong, Y.; Wang, H.; Wang, S.; Yu, H.; Liu, X.; Yang, L.; Jiang, X.; Li, l.; Li, L. J. Hepatol. 2009, 50, 1174-1183.
[30] Li, C.; Zheng, S.; You, H.; Liu, X.; Lin, M.; Yang, L.; Li, L. J. Hepatol. 2011, 54, 1205-1213.
[31] Rieck, P.W.; Kriegsch, J.; Jaeckel, C.; Hartmann, C. Ophthalmologe. 2004, 101, 73-79.
[32] Zhu, X.B.; Tang, S.B.; Luo, Y.; Huang, X.K. Chin. J. Ophthalmol. 2005, 41, 110-113.
[33] Dranoff, J.A.; Ogawa, M.; Kruglov, E.A.; Gaca, M.D.; Sevigny, J.; Robson, S.C. Am. J. Physiol. Gastrointest. Liver Physiol. 2004, 287, G417-424.
[34] Dranoff, J.A.; Krugloy E.A.; Abreu-Lanfranco, O.; Nguven, T.; Arora, G.; Jain, D. In Vivo. 2007, 21, 957-965.
[35] Chen, X.; Jiang, H.Q.; Yang, L.T.; Wang, Y.Z.; Hu, C.X. Acta. Anat. Sin. 2006, 37, 66-68.
[36] Trim, N.; Morgan, S.; Evans, M.; Issa, R.; Fine, D.; Afford, S. Am. J. Pathol. 2000, 156, 1235-1243.

苏拉明在肝纤维化大鼠肝星状细胞增殖和凋亡中的作用

Effects of suramin on proliferation and apoptosis of hepatic stellate cells of hepatic fibrosis rats

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	王番, 李锐莉, 王文军, 周晓燕, 刘美佑, 赵瑾怡, 文爱东, 王婧雯, 贾艳艳. α-乳香酸通过抑制TLR4介导的炎症通路改善急性肾损伤[J]. 中国药学(英文版), 2023, 32(7): 539-550.
[2]	赵炎葱, 王丽, 曾静静, 李景华. 新穿心莲内酯/β-环糊精包合物的分子结构及抗增殖作用研究[J]. 中国药学(英文版), 2023, 32(6): 427-434.
[3]	邓凯翔, 彭经宙, 张美泉, 林慧娟, 王小华, 何道兴, 朱俊明, 陈明光, 黄津. 牡蛎肽通过NF-κB/iNOS信号通路改善肝纤维化[J]. 中国药学(英文版), 2023, 32(6): 435-445.
[4]	赵炎葱, 龚慧媛, 李景华. 过表达的人β防御素-3可抑制结肠癌细胞增殖、迁移和细胞周期[J]. 中国药学(英文版), 2023, 32(4): 250-259.
[5]	阳丽梅, 王丽满, 黄旭慧, 庄捷. 华法林通过调控Gas6/Axl/PI3K/Akt/NF-κB通路影响肺癌细胞株的增殖和凋亡[J]. 中国药学(英文版), 2023, 32(3): 190-199.
[6]	陈培杰, 张云天. PTP1B抑制肝纤维化逆转期TRAIL诱导的肝星状细胞凋亡[J]. 中国药学(英文版), 2023, 32(11): 867-880.
[7]	郑吴殷晓, 李海平, 罗来春, 胡春玲, 尤朋涛. TOPC通过抑制PI3K/AKT/mTOR通路, 抑制miR-210, Atg7诱导H1975细胞凋亡[J]. 中国药学(英文版), 2023, 32(11): 881-892.
[8]	黄津, 邓凯翔, 黄美珍, 林高敏, 林媚, 练水梅, 张美泉. NF-κB抑制剂PDTC诱导人肝星状细胞LX-2凋亡的药理机制[J]. 中国药学(英文版), 2022, 31(9): 665-676.
[9]	王子翼, 刘晓岩, 朱元军, 刘晔, 张平平, 王银叶. W026B对大鼠全脑缺血再灌注损伤的保护作用[J]. 中国药学(英文版), 2022, 31(2): 108-116.
[10]	张明康, 陈宇玥, 周燕, 武新安. 槲皮素对四氯化碳致大鼠肝纤维化的缓解作用及其机制研究[J]. 中国药学(英文版), 2022, 31(11): 840-852.
[11]	韩春杨, 孙桃桃, 范广太, 刘亚伟, 刘翠艳. 黄精通过氧化应激和线粒体凋亡途径保护CCl4诱导的大鼠急性肝损伤[J]. 中国药学(英文版), 2021, 30(4): 306-318.
[12]	高克祥, 刘晓岩, 朱元军, 刘晔, 王银叶. B55γ蛋白对t-MCAO模型小鼠中W026B神经保护作用的影响[J]. 中国药学(英文版), 2020, 29(10): 711-718.
[13]	高建伟, 叶峰. 凋亡通路参与姜黄素抑制THP-1细胞炎症因子的转录[J]. 中国药学(英文版), 2019, 28(2): 100-113.
[14]	于快, 李茹一, 朱元军, 刘晓岩, 王银叶. 针对脑缺血再灌注损伤设计的双功能蛋白的脑保护作用优于单功能蛋白[J]. 中国药学(英文版), 2019, 28(11): 760-769.
[15]	权栩, 顾彩虹, 严峰, 高垚垚, 陈琳, 卫榕, 颜丙春, 胡荣. 猪胎盘肽通过提高TrkB和BDNF水平及促进神经母细胞增殖和分化延缓D-半乳糖诱导的小鼠衰老[J]. 中国药学(英文版), 2019, 28(10): 739-748.